Download the New Oncology Research Brief from Precision Health Economics
As healthcare spending continues to rise, payers and providers struggle to accurately measure value to patients, and with health systems all over the world shifting towards paying for value, not just volume, these efforts have never been more important.
Jeremy Schafer Addresses Sanofi/Regeneron’s dupilumab in BioPharm Insight
Precision for Value’s Jeremy Schafer comments on pricing and reimbursement of dupilumab, Sanofi/Regeneron’s first atopic dermatitis biologic, in BioPharm Insight.
Precision for Value’s Hepatitis C Survey Discussed in Managed Healthcare Executive: Here’s What’s Missing
Precision for Value’s Jeremy Schafer highlights what can be done to encourage payers to ease coverage policies for these drugs in the next wave of HCV treatment.
Schafer Discusses Hepatitis C Drug Safety Concerns in Drug Topics
Precision for Value’s Jeremy Schafer discusses safety concerns over some hepatitis C drugs in the latest edition of Drug Topics.
Commentary: Why Value-Based Pricing’s Time Has Come, and It’s Here to Stay
PHE economist Jason Shafrin talks prices, politics, and the problem of monopolies with eyeforpharma’s Hugh Gosling.